BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that fifteen abstracts associated with the company’s ADC technology, antibody-based therapeutics and collaborator programs will be presented at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) to be held April 14-18, 2007, at the Los Angeles Convention Center, Los Angeles, CA. In addition, Peter D. Senter, Ph.D., Vice President, Chemistry at Seattle Genetics will present during an educational session entitled “Novel Approaches to Drug Delivery in Cancer” on April 14, 2007 from 8:00 a.m. to 10:00 a.m. Dr. Senter’s presentation is titled “Potent Immunoconjugates for Cancer Therapy.”
